BIOFLOW-DAPT one-year-data demonstrated non-inferiority and a good safety profile for the Orsiro® Mission drug-eluting stent (DES) compared to Resolute Onyx DES (p
Los resultados del estudio MATRIX muestran que la alta precisión en la detección de los sistemas DAI DX con un solo cable para los episodios de FA (99,7 % para episodios ≥1 h), combinada con el potente rendimiento de transmisión de BIOTRONIK Home Monitoring®, permite la monitorización remota fiable de la FA subclínica recomendada por las guías. Los resultados se publicaron en Europace a principios de esta semana. 1MATRIX evaluó la utilidad del sistema DAI DX (detección de la señal auricular mediante un dípolo flotante integrado en el cable del DAI) para la monitorización remota de los episodios de alta frecuencia auricular (AHRE) y la evolución de su duración. Además, el estudio analizó las implicaciones clínicas de la detección y la evolución de los AHRE. El resultado del estudio debe interpretarse en el contexto de las directrices sobre la FA de 2020 de la Sociedad Europea de Cardiología, que recomiendan la monitorización remota de los AHRE detectados con disp
In the first-in-human study BIOMAG-I, BIOTRONIK’s new-generation DREAMS 3G resorbable magnesium scaffold (RMS) showed significantly lower in-scaffold late lumen loss (LLL) than its predecessor at 12 months as well as excellent safety and efficacy. Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results in the late breaking trial session at the EuroPCR course.1 At one-year follow-up, BIOMAG-I data confirmed the excellent safety profile of DREAMS 3G RMS with a low target lesion failure rate of 2.6%. Neither cardiac death and myocardial infarction occurred, nor scaffold thrombosis was reported. After completion of the resorption, the in-scaffold LLL was 0.24±0.36 mm, comparable to contemporary drug-eluting stents (DES).2 “At the end of the scaffold resorption, at 12 months the data showed, that the DREAMS 3G scaffold has an excellent safety and efficacy profile”, said Prof Michael Haude, Rheinland Klinikum, Germany. “The late lumen loss is not just 38% better
BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months.1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Rutherford Class 2-4 disease. Patients were randomized 1:1 to either the Passeo-18 Lux DCB or In.Pact Admiral DCB for the treatment of stenotic, non-stented restenotic or occlusive lesions in the femoropopliteal artery. Baseline patient and lesion characteristics were comparable across both arms. As presented at Paris Vascular Insights in November 2023, the rate of clinically driven target lesion revascularization (CD-TLR)
EuroPCR, the world-leading course in interventional cardiovascular medicine, is an annual event organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI). This renowned congress gathers cardiovascular professionals from around the globe to discuss cutting-edge innovations, refine practical skills, and improve patient outcomes.Join us in Paris to advance cardiovascular care!
BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. BIOTRONIK, founded in Berlin, Germany, in 1963 is a pioneer in implantable pacemakers, defibrillators, and vascular intervention for 60 years. BIOTRONIK’s presence in Singapore began in 2012, and in 2016, the company inaugurated its first manufacturing site, complementing its high-quality manufacturing sites in Germany, Switzerland and the United States. Now in 2023, the new facility has been designed with an emphasis on workspace agility for modern, optimized collaboration. The new site includes several spacious cleanrooms and laboratories developing and manufacturing state-of-the art Cardiac Rhythm Management (CRM) devices. “We are excited to be the first major manufacturer in the cardiac rhythm mana
BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and endovascular solutions, proudly announces a multinational distribution partnership with Texray, the pioneering developer of a groundbreaking radiation protection textile. In this collaboration BIOTRONIK will distribute Texray's head and neck protectors starting in selected European and Middle Eastern countries. Both partners aim to raise awareness about the critical importance of radiation protection for healthcare professionals, who serve in environments where radiation exposure is an inherent occupational risk. “Texray's radiation protective textiles complement BIOTRONIK’s product portfolio, enhancing our ability to offer customers comprehensive protection solutions. We are delighted to expand our offering, ensuring that healthcare professionals have a range of radiation protection options to support their safety in their daily work,” says John Brumfield, Global Vice President Marketing CRM at BIOTR
Find useful downloadable assets and press kits
